


Modernization, Where Are We?

Dan Solis, FDA
Assistant Commissioner for Import Operations



Updates-FDA



FDA Organization Chart - Office of Inspections and Investigations (OII)

Effective Oct. 1, 2024

Directly impacted by reorganization that took effect on Oct. 1, 2024 (i.e., shifts of functions, resources and/or personnel)

Department of Health And Human Services Food and Drug Administration Office of Inspections and Investigations

Associate Commissioner for Inspections and Investigations

Office of Field Operations & Response

Organizational Quality Staff

Office of Emergency Response Office of Field Regulatory Operations?

Office of Business Informatics & Solutions Management

Division of Regulatory Business Informatics & Solutions Division of Instructional Systems & Technology Division of Import Business Informatics & Solutions Division of Solutions Planning. Management & Governance Division of Work Planning & Analytics

Office of Training Education & Development

Division of Multi-Program, Leadership & Management Training Division of Programmatic Training

Office of Import Operations

Division of Targeting & Analysis **Division of Import Operations** Division of Analysis and Program Evaluation Division of Southwest Imports Division of Planning & Public Response Division of Southeast Imports Division of Northeast Imports Division of Northern Border Imports **Division of West Coast Imports**

Office of Criminal Investigations

Chicago Field Office Metro-Washington Field Office New York Field Office Los Angeles Field Office Miami Field Office Kansas City Field Office

Office of Management

Office of Budget, Facilities & Travel Support Office of Workforce Management

Office of Bioresearch Monitoring Inspectorate

Division of Bioresearch Monitoring Inspectorate (I-IV) Division of Bioresearch Monitoring Global Operations

Office of Biologics Inspectorate

Biologics Global Operations Staff

Division of Biologics Inspectorate (I-III) Division of Biotechnology Inspectorate

Office of Medical **Devices & Radiological** Health Inspectorate

Division of Medical Device & Radiological Health Inspectorate (I-IV)

Division of Mammography & Radiological Health Inspectorate

Division of Medical Device & Radiological Health Global Operations

Office of Human & Animal Drug Inspectorate

Division of Human & Animal Drug Inspectorate (I-VI) Division of Human & Animal Drug Foreign Inspectorate Division of Human & Animal Drug Global Operations

Office of Animal Food Inspectorate


Division of Animal Food Inspectorate (I-II)

Office of Human Food Inspectorate[‡]

Office of Human Food East Inspectorate Office of Human Food Central Inspectorate Office of Human Food West Inspectorate Office of Global & Specialty Human Food Inspectorate

†Includes Division of Tobacco Inspectorate Includes specialized teams for products such as infant formula

Updates: Office of Import Operations (OIO)



DIVISION OF TARGETING AND ANALYSIS

Harnessing intelligence, advanced technology, and comprehensive risk analytics to target import shipments of FDA regulated commodities which pose a threat to the health, safety, and security of the American public.



Data Analysis and Intelligence Research for risk-informed decision-making.



Receives and reviews Prior Notice and intelligence data



Develop methods for threat analysis, workplanning and resource allocation.



Recommends compliance actions for violations Prior Notice regulation.



Supply Chain Analysis



A liaison to Law Enforcement Agencies for the FDA.

Global Business Identifier (GBI)

In its current design, the GBI test is intended to:

- ✓ Examine the potential for identifiers to improve supply chain visibility and traceability
- ✓ Allow for more efficient customs procedures to expedite legitimate trade
- ✓ Support more secure, streamlined, cost-effective trade operations
- ✓ Operate within the Automated Commercial Environment (ACE) platform
- Enable volunteer trade participants to submit one or more global entity identifiers for the manufacturer, shipper, seller, exporter, distributor, and packager via the Automated Broker Interface (ABI)

Potential Benefits

- Streamlined Facilitation better assess and identify lower risk and highly compliant firms and products
- Secure Supply Chains helps authenticate and verify supply chains assisting entities in managing risk
- Whole-of-Customs Coordination PGAs can better harmonize risk decisionmaking across 1USG
- Shape the Future of GBI-Enabled Traceability trade participation will inform the evolution of the GBI test, which seeks enhancements to better meet trade and 1USG's supply chain traceability needs

Global Business Identifier (GBI)

- Progress to date:
 - In 2023, FDA partnered with CBP in co-leading the GBI test to jointly explore how identifiers could be leveraged to reduce redundancies
 - Continue to collaborate in evaluating GBI data elements to determine feasibility of a unique identifier solution to improve 1USG's ability to identify higher-risk shipments and facilitate legitimate trade
 - Continue to assess the impact of identifiers on efficiencies for both trade and PGAs

Entity Identifier Name	Entity Identifier Owner
Legal Entity Identifier (LEI) 20-digit, alphanumeric identifier with underlying reference data elements unique to a legal entity. Over 2.2 million LEIs issued worldwide.	GLEIF Enabling global identity Protecting digital trust
Global Location Number (GLN) 13-digit numeric identifier with varying sets of underlying reference data elements that are customizable to location, function, and operations. Over 2 million companies utilize GS1 Standards.	(GS1
Data Universal Numbering System (DUNS) 9-digit numeric and non-indicative identifier that identifies unique business establishments with a library of over 200 reference data elements. Over 300 million DUNS issued worldwide.	dun & bradstreet

Silicon Valley Innovation Project (SVIP)

Objectives

 Collaborate with CBP in adopting interoperability standards, facilitate legitimate trade, accepting data from traditional and non-traditional actors via testing data exchange and messaging using verifiable credentials

• Purpose

- Align FDA's data needs with CBP's technological advances for seamless, secure transactions
- Showcase thought leadership in streamlining the import process by improving verification of supply chains
- Explore supply chain transparency and compliance with FDA's Food Traceability Rule

Silicon Valley Innovation Program (SVIP)





Progress

- Began collaborating with CBP and associated contractors in 2023
- Partnered on technical changes to support the November 2024 technical demonstration
- Collaborated with Mesur.io (contractor) on the food safety portion of the test to identify verifiable credentials of interest to FDA

Potential Benefits

- Expedited clearance with verifiable credential-based, pre-manifest data
- Transparent supply chains to reduce waste and spoilage
- Reduced paperwork/data entry, and preparation for future digital trade environments



